Exicure, Inc. (XCUR) |
|
0.98 0.08 (8.89%)
|
06-06 11:53 |
|
Open: |
0.9 |
Pre. Close: |
0.9 |
|
High:
|
0.98 |
Low:
|
0.9 |
|
Volume:
|
4,122 |
Market Cap:
|
8(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 2:21:49 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.36 One year: 1.61 |
| Support: |
Support1: 0.82 Support2: 0.68 |
| Resistance: |
Resistance1: 1.16 Resistance2: 1.37 |
| Pivot: |
0.91  |
| Moving Average: |
MA(5): 0.9 MA(20): 0.95
MA(100): 1.1 MA(250): 1.5 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 29.2 %D(3): 21.3 |
| RSI: |
RSI(14): 53.2 |
| 52-week: |
High: 4.94 Low: 0.62 |
| Average Vol(K): |
3-Month: 21 (K) 10-Days: 12 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XCUR ] has closed below upper band by 27.4%. Bollinger Bands are 10.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.9 - 0.91 |
0.91 - 0.91 |
|
Low:
|
0.84 - 0.84 |
0.84 - 0.85 |
|
Close:
|
0.89 - 0.9 |
0.9 - 0.91 |
|
Company Description |
|
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. |
Headline News |
Fri, 02 Jun 2023
North American Morning Briefing: Stock Futures -2- - Morningstar
Fri, 26 May 2023
Exicure, Inc. Announces Support of CEO in its Ongoing Exploration ... - Business Wire
Fri, 19 May 2023
North American Morning Briefing: Powell on Tap -2- - Morningstar
Fri, 19 May 2023
Exicure Inc Receives Notice of NonCompliance from Nasdaq Stock ... - Best Stocks
Wed, 10 May 2023
Should You Buy Exicure Inc (XCUR) Stock After it Has Risen 2.78% in a Week? - InvestorsObserver
Thu, 04 May 2023
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
8 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
56.9 (%) |
|
% Held by Institutions
|
12.4 (%) |
|
Shares Short
|
120 (K) |
|
Shares Short P.Month
|
123 (K) |
Stock Financials |
|
EPS
|
-0.57 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3 |
|
Profit Margin (%)
|
-9 |
|
Operating Margin (%)
|
-6.4 |
|
Return on Assets (ttm)
|
-2.6 |
|
Return on Equity (ttm)
|
-19.8 |
|
Qtrly Rev. Growth
|
928 |
|
Gross Profit (p.s.)
|
1.08 |
|
Sales Per Share
|
3.44 |
|
EBITDA (p.s.)
|
-0.08 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-36 (M) |
|
Levered Free Cash Flow
|
-20 (M) |
Stock Valuations |
|
PE Ratio
|
-1.75 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.32 |
|
Price to Sales
|
0.28 |
|
Price to Cash Flow
|
-0.24 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
